Abstract:Type 2 diabetes mellitus (T2DM) is a metabolic disease and a major challenge to healthcare systems around the world. Dipeptidyl peptidase IV (DPP-4), a serine protease, has been rapidly emerging as an effective therapeutic target for the treatment for T2DM. In this study, a series of novel DPP-4 inhibitors, featuring the pyrazole-3-carbohydrazone scaffold, have been discovered using an integrated approach of structure-based virtual screening, chemical synthesis, and bioassay. Virtual screening of SPECS Database, followed by enzymatic activity assay, resulted in five micromolar or low-to-mid-micromolar inhibitory level compounds (15) with different scaffold. Compound 1 was selected for the further structure modifications in considering inhibitory activity, structural variability, and synthetic accessibility. Seventeen new compounds were synthesized and tested with biological assays. Nine compounds (6e, 6g, 6kl, and 7ae) were found to show inhibitory effects against DPP-4. Molecular docking models give rational explanation about structureactivity relationships. Based on eight DPP-4 inhibitors (15, 6e, 6k, and 7d), the best pharmacophore model hypo1 was obtained, consisting of one hydrogen bond donor (HBD), one hydrogen bond acceptor (HBA), and two hydrophobic (HY) features. Both docking models and pharmacophore mapping results are in agreement with pharmacological results. The present studies give some guiding information for further structural optimization and are helpful for future DPP-4 inhibitors design.

Recent advances in peptidomimetic dipeptidyl peptidase Ⅳ inhibitors

Dipeptidyl Peptidase IV(DPP IV): a Novel Emerging Target for the Treatment of Type 2 Diabetes

Recent Advances in Non-Peptidomimetic Dipeptidyl Peptidase 4 Inhibitors: Medicinal Chemistry and Preclinical Aspects

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Novel DPP-4 Inhibitors Against Diabetes

The Potential DPP-4 Inhibitors from Xiao-Ke-An Improve the Glucolipid Metabolism Via the Activation of AKT/GSK-3β Pathway.

Design, Synthesis and Biological Evaluation of Novel Imidazolone Derivatives As Dipeptidyl Peptidase 4 Inhibitors.

Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors.

Design, synthesis and evaluation of a series of novel long-acting dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes

The Research Progress of DPP-4 Inhibitors.

The Research Progress of DPP-4 Inhibitors

The Highly Potent and Selective Dipeptidyl Peptidase IV Inhibitors Bearing a Thienopyrimidine Scaffold Effectively Treat Type 2 Diabetes.

Synthesis and Biological Evaluation of Novel Benzyl-Substituted (S)-Phenylalanine Derivatives As Potent Dipeptidyl Peptidase 4 Inhibitors.

Synthesis and Biological Evaluation of Azobicyclo[3.3.0] Octane Derivatives As Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes

Progress on Glucosidase Inhibitors

Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.

Recent advances and structure-activity relationship studies of DPP-4 inhibitors as anti-diabetic agents

Discovery of Food-Derived Dipeptidyl Peptidase IV Inhibitory Peptides: A Review

Design, Synthesis and SAR Studies of Novel and Potent Dipeptidyl Peptidase 4 Inhibitors

Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes

Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment